DRUG DISAPPOINTMENT: After strong results in a midstage study, an Alzheimer's drug Pfizer Inc. is developing with a partner unexpectedly failed to work in a late-stage patient test. WHAT'S NEXT: Scientists at Pfizer and Medivation Inc. will analyze the data to try ...

Shares of Medivation Inc. plunged Wednesday after the failure of Dimebon, an Alzheimer's drug the company is developing with Pfizer Inc. Medivation stock lost about two-thirds of its value and fell to an annual low Wednesday morning. Before the market opened, Medivation and Pfizer said ...

LONDON (Reuters) - New imaging technology suggests an experimental drug for Alzheimer's reduces clumps of plaque in the brain by around 25 percent, lifting hopes for a medicine that disappointed in clinical tests two years ago. Bapineuzumab -- being developed by Pfizer Inc, Irish drugmaker Elan Corp and Johnson & Johnson -- is a potential game-changer because it could be the first ...

NEW YORK (Reuters Health) - Elderly adults with poor vision, particularly untreated vision problems, may have a higher risk of developing dementia than those with better vision, a new study suggests. Researchers found that among 625 older Americans with initially normal cognition, those who said they had poor vision even with corrective lenses were more likely to develop dementia over the ...